Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | Chief Financial Officer | July 23, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date July 23, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,287 |
Reported balance
After 2026-07-23 transaction · row 1
1 source rowRow 1 · 2026-07-23 · Grant · Acquired 47,250 · Balance 101,287 F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.01 · Expires 2036-07-22 | Direct | 94,500 |
Reported balance
After 2026-07-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-23 · Grant · Acquired 94,500 · Balance 94,500 F2: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
F2: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 94,500 | $0.00 Strike: $22.01 | $0.00 |
DisclosureSEC source: 0001994071-26-000006 · form4-07272026_040705.xml · derivative · entry 2 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,500 Underlying: Common Stock · 94,500 shares Expires 2036-07-22 F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantCommon Stock | 47,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001994071-26-000006 · form4-07272026_040705.xml · nonDerivative · entry 1 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,287 F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:26 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001994071-26-000004 · form4-06172026_090615.xml · derivative · entry 3 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2033-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:26 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 60,000 | $18.23 | $1,093,800.00 |
DisclosureSEC source: 0001994071-26-000004 · form4-06172026_090615.xml · nonDerivative · entry 2 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,037 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. F2 · price: The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:26 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 60,000 | $1.05 | $63,000.00 |
DisclosureSEC source: 0001994071-26-000004 · form4-06172026_090615.xml · nonDerivative · entry 1 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 23:46 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionStock option (right to buy) · Derivative | 39,713 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001994071-26-000002 · form4-04032026_110446.xml · derivative · entry 6 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,713 shares Expires 2032-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 23:46 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionStock option (right to buy) · Derivative | 31,848 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001994071-26-000002 · form4-04032026_110446.xml · derivative · entry 5 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 31,848 shares Expires 2033-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 23:46 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 1,344 | $22.48 | $30,213.12 |
DisclosureSEC source: 0001994071-26-000002 · form4-04032026_110446.xml · nonDerivative · entry 4 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,037 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. F3 · price: The weighted average purchase price for the transaction report was $22.48, and the range of prices were between $22.45 and $22.56, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 23:46 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 63,656 | $21.91 | $1,394,702.96 |
DisclosureSEC source: 0001994071-26-000002 · form4-04032026_110446.xml · nonDerivative · entry 3 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,381 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. F2 · price: The weighted average purchase price for the transaction report was $21.91, and the range of prices were between $21.44 and $22.44, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 23:46 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 39,713 | $1.35 | $53,612.55 |
DisclosureSEC source: 0001994071-26-000002 · form4-04032026_110446.xml · nonDerivative · entry 2 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 23:46 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 31,848 | $1.05 | $33,440.40 |
DisclosureSEC source: 0001994071-26-000002 · form4-04032026_110446.xml · nonDerivative · entry 1 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 22:59 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 207,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001415889-25-020787 · form4-07312025_100711.xml · derivative · entry 1 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,000 Underlying: Common Stock · 207,000 shares Expires 2035-07-28 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 23:26 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionStock option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001415889-24-023809 · form4-09202024_110913.xml · derivative · entry 3 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,848 Underlying: Common Stock · 42,000 shares Expires 2033-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Reporting Person's Form 3 filed on October 12, 2023 contains a scrivener's error reflecting an exercise price of $1.06 instead of the correct exercise price of $1.05. F4 · derivative.exercise_date: 25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 23:26 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 14,380 | $16.01 | $230,223.80 |
DisclosureSEC source: 0001415889-24-023809 · form4-09202024_110913.xml · nonDerivative · entry 2 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,476 F1 · kind: The shares were sold pursuant to sell to cover transactions. F2 · price: The weighted average sale price for the transaction report was $16.01, and the range of prices were between $15.97 and $16.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 23:26 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 42,000 | $1.05 | $44,100.00 |
DisclosureSEC source: 0001415889-24-023809 · form4-09202024_110913.xml · nonDerivative · entry 1 Rosett Max · CIK 0001994071 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 21:43 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 190,000 | $0.00 Strike: $12.92 | $0.00 |
DisclosureSEC source: 0001415889-24-021230 · form4-08132024_090853.xml · derivative · entry 1 Rosett Max · CIK 0001994071 · EVP, Operations & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2034-08-08 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:11 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001415889-24-013577 · form4-05172024_090559.xml · derivative · entry 1 Rosett Max · CIK 0001994071 · EVP, Operations & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-15 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on May 16, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 01:53 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 175,000 | $0.00 Strike: $16.57 | $0.00 |
DisclosureSEC source: 0001415889-24-002121 · form4-02012024_010250.xml · derivative · entry 1 Rosett Max · CIK 0001994071 · EVP, OPERATIONS & INTERIM CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2034-01-30 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on January 31, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.